Anixa Biosciences is trading at $3.62 (6.5% up) in after-hours, rebounding from recent biotech-sector weakness and volatility earlier this week.
- The move follows a broader risk-on shift in the market after a challenging week for growth and healthcare stocks.
- While no new company-specific catalyst was reported today, recent momentum has been supported by insider buying, positive clinical-trial progress, and patent updates.